金斯瑞生物科技領導層入圍「年度企業家獎」決賽
GenScript Biotech leaders named finalists for Entrepreneur of the Year award
2026年4月23日，金斯瑞生物科技股份有限公司（GenScript Biotech Corporation）達成了一項重大的里程碑，其執行長邵煒慧（Sherry Shao）與共同創辦人章方良博士（Dr.
On April 23, 2026, GenScript Biotech Corporation achieved a significant milestone as its CEO, Sherry Shao, and Co-Founder, Dr.
Frank Zhang）獲選為享有盛譽的「2026年紐澤西州年度創業家獎（Entrepreneur Of The Year® 2026 New Jersey Award）」最終候選人。
Frank Zhang, were named finalists for the prestigious Entrepreneur Of The Year® 2026 New Jersey Award.
此獎項由安永聯合會計師事務所（EY）主辦，旨在表彰展現卓越創新、成長與長期社會影響力的領導者。
Organized by Ernst & Young LLP (EY), this honor recognizes leaders who demonstrate exceptional innovation, growth, and long-term societal impact.
金斯瑞於2002年在紐澤西州成立，已從一家開創性的基因合成公司，發展為全球性的生物科技巨擘。
Founded in New Jersey in 2002, GenScript has evolved from a pioneering gene synthesis firm into a global biotechnology powerhouse.
時至今日，該公司服務範圍遍及全球100多個國家，致力於讓生物技術變得普及與高效，並持續為研究人員與醫藥創新者提供支援。
Today, the company serves researchers and pharmaceutical innovators across more than 100 countries, driven by a mission to make biotechnology accessible and efficient.
章方良博士因確立了公司的基礎願景而備受推崇，而於2023年獲任命為輪值執行長的邵煒慧，則因帶領組織經歷了全球大規模成長與轉型而獲得認可。
Dr.
此次獲選為35位區域候選人之一，突顯了金斯瑞在生命科學領域的深遠影響力。
Zhang is celebrated for establishing the company's foundational vision, while Sherry Shao, appointed as rotating CEO in 2023, is recognized for steering the organization through a period of substantial global growth and transformation.
紐澤西州的區域優勝者將於2026年6月4日揭曉，獲選者將晉級參與11月的全國性比賽。
Being named among 35 regional finalists highlights GenScript's enduring influence within the life sciences sector.
此項提名證明了在現代生物科技領域中，科學卓越性與願景商業領導力的結合。
The regional winners for New Jersey will be revealed on June 4, 2026, with the successful candidates moving on to the national competition in November.
